Well...very little commentary on this release which will probably surprise management (if they read the forum) noting the recent request/demands for the imminent release of outcomes from the symposium.
without repeating the release's statements, I can only say that the company is/must/should be well on the way to realising a commercial venture around at least two primary candidates for clinical validation.
Very happy with the release and confirmation, to some extent, of the Westmead "in-live' results. The commercial nature of further detail is unlikely, in my view, until at least the agreed way forward is released.
In summary, the global acknowledgement of the MK role in many diseases will see this company valued much higher once the money is on the table for that first commercial contract. Perhaps when the first domino falls the market may get the bigger picture and potential.
CDY Price at posting:
51.0¢ Sentiment: Buy Disclosure: Held
